Bank of New York Mellon’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.27B | Sell |
14,084,483
-2,653,065
| -16% | -$222M | 0.21% | 82 |
|
|
2026
Q1 | $1.34B | Sell |
16,737,548
-755,041
| -4% | -$62.2M | 0.25% | 74 |
|
|
2025
Q4 | $1.49B | Sell |
17,492,589
-1,517,638
| -8% | -$125M | 0.26% | 69 |
|
|
2025
Q3 | $1.48B | Buy |
19,010,227
+1,423,365
| +8% | +$111M | 0.27% | 65 |
|
|
2025
Q2 | $1.38B | Sell |
17,586,862
-69,276
| -0.4% | -$5.17M | 0.26% | 73 |
|
|
2025
Q1 | $1.28B | Sell |
17,656,138
-468,983
| -3% | -$33.6M | 0.25% | 74 |
|
|
2024
Q4 | $1.34B | Sell |
18,125,121
-181,202
| -1% | -$12.7M | 0.25% | 72 |
|
|
2024
Q3 | $1.21B | Sell |
18,306,323
-1,476,586
| -7% | -$107M | 0.22% | 89 |
|
|
2024
Q2 | $1.83B | Buy |
19,782,909
+809,605
| +4% | +$71.7M | 0.35% | 51 |
|
|
2024
Q1 | $1.81B | Buy |
18,973,304
+1,644,869
| +9% | +$138M | 0.35% | 52 |
|
|
2023
Q4 | $1.32B | Sell |
17,328,435
-280,406
| -2% | -$19.5M | 0.27% | 72 |
|
|
2023
Q3 | $1.22B | Sell |
17,608,841
-99,499
| -0.6% | -$8M | 0.27% | 74 |
|
|
2023
Q2 | $1.67B | Sell |
17,708,340
-511,673
| -3% | -$44.5M | 0.35% | 51 |
|
|
2023
Q1 | $1.51B | Sell |
18,220,013
-989,952
| -5% | -$77.8M | 0.33% | 55 |
|
|
2022
Q4 | $1.43B | Sell |
19,209,965
-1,057,673
| -5% | -$81.5M | 0.33% | 58 |
|
|
2022
Q3 | $1.67B | Sell |
20,267,638
-1,363,348
| -6% | -$131M | 0.41% | 45 |
|
|
2022
Q2 | $2.06B | Sell |
21,630,986
-215,556
| -1% | -$22.3M | 0.47% | 35 |
|
|
2022
Q1 | $2.57B | Sell |
21,846,542
-343,679
| -2% | -$38.6M | 0.5% | 33 |
|
|
2021
Q4 | $2.87B | Sell |
22,190,221
-137,006
| -0.6% | -$16M | 0.52% | 31 |
|
|
2021
Q3 | $2.53B | Sell |
22,327,227
-1,030,088
| -4% | -$118M | 0.49% | 32 |
|
|
2021
Q2 | $2.42B | Buy |
23,357,315
+186,344
| +0.8% | +$17.6M | 0.47% | 35 |
|
|
2021
Q1 | $1.94B | Buy |
23,170,971
+1,387,141
| +6% | +$117M | 0.4% | 49 |
|
|
2020
Q4 | $1.99B | Buy |
21,783,830
+1,181,085
| +6% | +$98M | 0.43% | 46 |
|
|
2020
Q3 | $1.64B | Buy |
20,602,745
+257,592
| +1% | +$20.1M | 0.41% | 50 |
|
|
2020
Q2 | $1.41B | Buy |
20,345,153
+693,713
| +4% | +$49.3M | 0.38% | 52 |
|
|
2020
Q1 | $1.24B | Buy |
19,651,440
+1,039,665
| +6% | +$75M | 0.41% | 50 |
|
|
2019
Q4 | $1.45B | Sell |
18,611,775
-845,121
| -4% | -$66M | 0.37% | 52 |
|
|
2019
Q3 | $1.43B | Sell |
19,456,896
-987,624
| -5% | -$69.4M | 0.39% | 53 |
|
|
2019
Q2 | $1.26B | Sell |
20,444,520
-298,182
| -1% | -$18M | 0.34% | 60 |
|
|
2019
Q1 | $1.32B | Sell |
20,742,702
-420,759
| -2% | -$24M | 0.37% | 54 |
|
|
2018
Q4 | $1.08B | Sell |
21,163,461
-778,869
| -4% | -$39.4M | 0.34% | 60 |
|
|
2018
Q3 | $1.27B | Sell |
21,942,330
-453,540
| -2% | -$22.2M | 0.33% | 66 |
|
|
2018
Q2 | $1.09B | Sell |
22,395,870
-1,519,842
| -6% | -$70.9M | 0.3% | 70 |
|
|
2018
Q1 | $1.11B | Buy |
23,915,712
+1,172,940
| +5% | +$50.9M | 0.31% | 68 |
|
|
2017
Q4 | $854M | Buy |
22,742,772
+7,132,332
| +46% | +$262M | 0.22% | 83 |
|
|
2017
Q3 | $569M | Sell |
15,610,440
-303,168
| -2% | -$11.6M | 0.16% | 126 |
|
|
2017
Q2 | $627M | Buy |
15,913,608
+9,833,178
| +162% | +$359M | 0.18% | 110 |
|
|
2017
Q1 | $191M | Buy |
6,080,430
+561,366
| +10% | +$17.6M | 0.05% | 371 |
|
|
2016
Q4 | $172M | Buy |
5,519,064
+11,289
| +0.2% | +$366K | 0.05% | 386 |
|
|
2016
Q3 | $221M | Sell |
5,507,775
-59,022
| -1% | -$2.22M | 0.07% | 307 |
|
|
2016
Q2 | $185M | Sell |
5,566,797
-292,911
| -5% | -$10M | 0.06% | 345 |
|
|
2016
Q1 | $172M | Sell |
5,859,708
-1,619,523
| -22% | -$44.7M | 0.05% | 357 |
|
|
2015
Q4 | $197M | Sell |
7,479,231
-560,217
| -7% | -$14.5M | 0.06% | 325 |
|
|
2015
Q3 | $190M | Sell |
8,039,448
-2,974,584
| -27% | -$71.8M | 0.06% | 341 |
|
|
2015
Q2 | $261M | Buy |
11,014,032
+834,138
| +8% | +$18.8M | 0.07% | 292 |
|
|
2015
Q1 | $242M | Buy |
10,179,894
+2,578,590
| +34% | +$57.8M | 0.06% | 338 |
|
|
2014
Q4 | $161M | Buy |
7,601,304
+610,314
| +9% | +$12.3M | 0.04% | 414 |
|
|
2014
Q3 | $119M | Buy |
6,990,990
+112,056
| +2% | +$1.77M | 0.03% | 513 |
|
|
2014
Q2 | $98.4M | Sell |
6,878,934
-580,536
| -8% | -$7.87M | 0.03% | 593 |
|
|
2014
Q1 | $92.2M | Sell |
7,459,470
-270,696
| -4% | -$3.12M | 0.03% | 609 |
|
|
2013
Q4 | $84.7M | Sell |
7,730,166
-1,113,486
| -13% | -$12.6M | 0.02% | 633 |
|
|
2013
Q3 | $103M | Sell |
8,843,652
-332,610
| -4% | -$3.89M | 0.03% | 542 |
|
|
2013
Q2 | $103M | Buy |
+9,176,262
| New | +$109M | 0.03% | 515 |
|
Other funds holding EW
WT
Bank of New York Mellon's EW Position: Q2 2026 in Review
Bank of New York Mellon reduced its Edwards Lifesciences (EW) stake by 16% in Q2 2026, selling an estimated $222M and leaving 14,084,483 shares worth $1.27B. The position accounts for 0.21% of the portfolio, ranked #82.
Bank of New York Mellon first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.87B in Q4 2021. 833 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Bank of New York Mellon held 14,084,483 shares of Edwards Lifesciences worth $1.27B as of Q2 2026.
- Bank of New York Mellon sold 2,653,065 Edwards Lifesciences shares in Q2 2026, an estimated $222M.
- Edwards Lifesciences made up 0.21% of Bank of New York Mellon's portfolio in Q2 2026, its #82 holding.
- Bank of New York Mellon first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
- Bank of New York Mellon's Edwards Lifesciences position peaked at $2.87B in Q4 2021.
- 833 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.